https://www.selleckchem.com/mTOR.html
Tumors were reduced but not absent in DEN-treated liver-specific Zhx2 knockout mice, suggesting that Zhx2 acts in both hepatocytes and nonparenchymal cells to inhibit tumor formation. Analysis of data from the Cancer Genome Atlas and Clinical Proteomic Tumor Consortium indicated that ZHX2 messenger RNA and protein levels were significantly higher in patients with HCC and associated with clinical pathological parameters. Conclusion In contrast to previous studies in human hepatoma cell lines and other HCC mouse models showing that Zhx2 acts as a tum
Gefällt mir
Kommentar
Teilen
